Pre-made Nemolizumab benchmark antibody ( Whole mAb, anti-IL31RA/IL31R therapeutic antibody, Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-372

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-372 Category Tag

Product Details

Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017.

Products Name (INN Index)

Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody

INN Name

Nemolizumab

Target

IL31RA

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG2

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2014

Companies

Chugai Pharmaceutical,Galderma,Maruho

Conditions Approved

NA

Conditions Active

Atopic dermatitis,Prurigo nodularis,Pruritus

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL31RA

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide